Kris Sachsenmeier
Company: Compass Therapeutics
Job title: Vice President, Head of Translational Science
Seminars:
Roundtable Discussion: CD19, CD20, BCMA – What is the Optimal Target for Autoimmune Indications? 9:30 am
Comparing the therapeutic potential of CD19, CD20, and BCMA as targets for autoimmune diseases, considering immune cell populations and disease pathophysiology Evaluating safety and efficacy profiles of targeting these antigens, including off-target effects, potential for immune depletion, and long-term durability Exploring optimal strategies for T-cell engager development, including antigen selection, dosing regimens, and combination therapies…Read more
day: Day 2